Cardiovascular disease is the leading contributor to years lost due to disability or premature
death among adults. Current efforts focus on risk prediction and risk factor mitigation ‚which …

As precision medicine becomes increasingly relevant in healthcare, the field of
pharmacogenomics (PGx) also continues to gain prominence in the clinical setting. Leading …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

A new global pandemic of coronavirus disease 2019 (COVID-19) has resulted in high
mortality and morbidity. Currently numerous drugs are under expedited investigations …

Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study
of interindividual variations in DNA sequence related to drug response, into routine clinical …

Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …

Pharmacogenomics can enhance patient care by enabling treatments tailored to genetic
make-up and lowering risk of serious adverse events. As of June 2019, there are 132 …

Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …

The evidence for pharmacogenetics has grown rapidly in recent decades. However, the
strength of evidence required for the clinical implementation of pharmacogenetics is highly …

The outcome of first-episode psychosis (FEP) is highly variable, ranging from early
sustained recovery to antipsychotic treatment resistance from the onset of illness. For …